Artivion (NYSE:AORT) Trading Down 6.5% Following Analyst Downgrade

Artivion, Inc. (NYSE:AORT)’s stock price dropped 6.5% during trading on Friday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The company traded as low as $33.85 and last traded at $38.0110. Approximately 103,725 shares changed hands during trading, a decline of 68% from the average daily volume of 319,879 shares. The stock had previously closed at $40.65.

A number of other equities analysts have also recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $58.00 target price on shares of Artivion in a report on Monday, February 2nd. Oppenheimer reissued an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group dropped their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Finally, Citizens Jmp boosted their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $48.69.

Insider Activity at Artivion

In related news, insider John E. Davis sold 6,394 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $45.17, for a total value of $288,816.98. Following the completion of the transaction, the insider directly owned 198,842 shares of the company’s stock, valued at $8,981,693.14. This represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James P. Mackin sold 30,921 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the sale, the chief executive officer directly owned 800,993 shares in the company, valued at approximately $36,493,241.08. The trade was a 3.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 128,448 shares of company stock worth $5,793,361 over the last ninety days. 7.60% of the stock is currently owned by insiders.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

Hedge Funds Weigh In On Artivion

Large investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its position in shares of Artivion by 107.0% during the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its stake in Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after buying an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after buying an additional 1,032 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Artivion in the second quarter valued at approximately $669,000. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Artivion by 364.4% in the second quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock valued at $1,644,000 after acquiring an additional 41,487 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Trading Down 10.9%

The business’s 50-day moving average price is $43.60 and its 200-day moving average price is $42.87. The firm has a market capitalization of $1.72 billion, a PE ratio of 181.18 and a beta of 1.59. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.74%. The firm had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. The business’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.